Want to join the conversation?
$JW.A $JW.B reaffirmed its FY17 outlook of flat revenue and mid single-digits decline in adjusted EPS excluding FX, favorable impact from shifting to time-based journal subscription agreements, partial year revenue contribution and EPS dilution of the Atypon acquisition.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.